全文获取类型
收费全文 | 389篇 |
免费 | 29篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 9篇 |
妇产科学 | 1篇 |
基础医学 | 84篇 |
口腔科学 | 2篇 |
临床医学 | 33篇 |
内科学 | 32篇 |
皮肤病学 | 67篇 |
神经病学 | 87篇 |
特种医学 | 7篇 |
外科学 | 27篇 |
综合类 | 1篇 |
预防医学 | 23篇 |
眼科学 | 6篇 |
药学 | 22篇 |
肿瘤学 | 12篇 |
出版年
2024年 | 2篇 |
2023年 | 12篇 |
2022年 | 8篇 |
2021年 | 17篇 |
2020年 | 7篇 |
2019年 | 15篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 23篇 |
2015年 | 13篇 |
2014年 | 12篇 |
2013年 | 15篇 |
2012年 | 19篇 |
2011年 | 26篇 |
2010年 | 19篇 |
2009年 | 13篇 |
2008年 | 17篇 |
2007年 | 19篇 |
2006年 | 20篇 |
2005年 | 18篇 |
2004年 | 17篇 |
2003年 | 18篇 |
2002年 | 29篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 4篇 |
1998年 | 6篇 |
1997年 | 2篇 |
1995年 | 2篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1982年 | 1篇 |
1980年 | 2篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1944年 | 2篇 |
1932年 | 1篇 |
1927年 | 1篇 |
1925年 | 1篇 |
1907年 | 1篇 |
1906年 | 2篇 |
1905年 | 1篇 |
1904年 | 1篇 |
1899年 | 1篇 |
排序方式: 共有418条查询结果,搜索用时 15 毫秒
1.
Ioana Maris Sabine Dölle-Bierke Jean-Marie Renaudin Lars Lange Alice Koehli Thomas Spindler Jonathan Hourihane Kathrin Scherer Katja Nemat C. Kemen Irena Neustädter Christian Vogelberg Thomas Reese Ismail Yildiz Zsolt Szepfalusi Hagen Ott Helen Straube Nikolaos G. Papadopoulos Susanne Hämmerling Ute Staden Michael Polz Tihomir Mustakov Ewa Cichocka-Jarosz Renata Cocco Alessandro Giovanni Fiocchi Montserrat Fernandez-Rivas Margitta Worm Network for Online Registration of Anaphylaxis 《Allergy》2021,76(5):1517-1527
Background
Peanut allergy has a rising prevalence in high-income countries, affecting 0.5%–1.4% of children. This study aimed to better understand peanut anaphylaxis in comparison to anaphylaxis to other food triggers in European children and adolescents.Methods
Data was sourced from the European Anaphylaxis Registry via an online questionnaire, after in-depth review of food-induced anaphylaxis cases in a tertiary paediatric allergy centre.Results
3514 cases of food anaphylaxis were reported between July 2007 - March 2018, 56% in patients younger than 18 years. Peanut anaphylaxis was recorded in 459 children and adolescents (85% of all peanut anaphylaxis cases). Previous reactions (42% vs. 38%; p = .001), asthma comorbidity (47% vs. 35%; p < .001), relevant cofactors (29% vs. 22%; p = .004) and biphasic reactions (10% vs. 4%; p = .001) were more commonly reported in peanut anaphylaxis. Most cases were labelled as severe anaphylaxis (Ring&Messmer grade III 65% vs. 56% and grade IV 1.1% vs. 0.9%; p = .001). Self-administration of intramuscular adrenaline was low (17% vs. 15%), professional adrenaline administration was higher in non-peanut food anaphylaxis (34% vs. 26%; p = .003). Hospitalization was higher for peanut anaphylaxis (67% vs. 54%; p = .004).Conclusions
The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition.2.
The cytokine lymphotoxin (LT)α is known to play a role in B cell activation. As the engagement of the B cell antigen CD40 is known to lead to B cell proliferation and differentiation, we studied LTα expression in human B cells after CD40 ligation. We demonstrate that anti-CD40 monoclonal antibody (mAb) induces strong LTα mRNA and surface expression in human tonsil B cells. Induction of LTα mRNA and surface expression by CD40 ligation is inhibited by the protein tyrosine kinase (PTK) inhibitors herbimycin and genistein in a dose-dependent manner. The protein kinase C (PKC)-specific inhibitors sphingosine and bisindolylmaleimide caused negligible inhibition of anti-CD40-induced LTα mRNA and surface expression. No inhibition is observed with the protein kinase (PKA) inhibitors H89 and HA1004. Cross-linking of the transmembrane phosphatase CD45 to CD40 by using goat-anti-mouse F(ab')2 fragments strongly inhibits CD40-mediated LTα expression in human B cells, confirming the role of PTK activation in CD40-mediated induction of LTα expression. Inhibitors of the serine/threonine protein phosphatases PP1 and PP2A, okadaic acid and calyculin induce LTα mRNA expression. In contrast, cyclosporin A, an inhibitor of the serine/threonine phosphatase calcineurin has no effect on anti-CD40-induced LTα expression. These results suggest that induction of LTα expression in B cells following engagement of CD40 involves activation of protein tyrosine kinases. 相似文献
3.
Rohrmeier T Putzhammer A Schoeler A Sartor H Dallinger P Nöthen MM Propping P Knapp M Albus M Borrmann M Knothe K Kreiner R Franzek E Lichtermann D Rietschel M Maier W Klein HE Eichhammer P 《Psychiatric genetics》1999,9(4):169-175
hSKCa3 is a neuronal small conductance calcium-activated potassium channel, which contains a polyglutamine tract, encoded by a polymorphic CAG repeat in the gene. Since an association between longer alleles of this CAG repeat and bipolar disorder or schizophrenia has been reported, we genotyped the polymorphic CAG repeat in 91 German family trios of patients with bipolar disorder I and used the transmission disequilibrium test (TDT) to test for association. Applying a dichotomized model (< or = 19 or > 19 CAG triplets), we found no evidence for an association of longer alleles with bipolar disorder (TDT = 0.75, P = 0.386). Regarding the whole range of alleles, there was no preference in transmitting the larger of the two observed alleles from parents to the affected offspring. In parallel we performed an independent case-control study on German patients with bipolar disorder and schizophrenia. Again we did not detect an overrepresentation of longer CAG repeats in patients. Thus, our data do not support the hypothesis that longer CAG repeats in the hSkCa3 gene contribute to the susceptibility for bipolar disorder and schizophrenia. 相似文献
4.
Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings 总被引:3,自引:0,他引:3
Hranilovic D Schwab SG Jernej B Knapp M Lerer B Albus M Rietschel M Kanyas K Borrmann M Lichtermann D Maier W Wildenauer DB 《Molecular psychiatry》2000,5(1):91-95
The serotonergic (5-HT) system has been implicated in the etiopathogenesis of psychoses. Since the 5-HT transporter plays an important role in regulation of 5-HT transmission, its gene can be considered as a candidate for vulnerability to psychiatric disorders. Two polymorphic sites of the 5-HT transporter gene-5-HTTLPR, a VNTR in the 5' regulatory region, and a VNTR in the second intron-were studied in a sample of 61 families with schizophrenia for transmission disequilibrium. Each family contained at least two siblings affected with schizophrenia or schizoaffective disorder (mainly schizophrenic). One hundred and thirty-nine affected offspring with parental information for genotyping, were available for analysis. No preferential transmission of either short or long alleles of the promoter polymorphism was observed. However, a transmission distortion was detected for alleles of the intronic VNTR polymorphism (chi2TDT max =14.33; P = 0.0002; corrected P value = 0.0003) resulting in more frequent than expected transmission of the 12 repeat allele. This finding adds additional evidence to the idea that the serotonergic system may be involved in development of psychoses. Molecular Psychiatry (2000) 5, 91-95. 相似文献
5.
6.
Kiran Kumar Mudnakudu Nagaraju Magda Babina Margitta Worm 《Experimental dermatology》2013,22(11):742-747
Proteasome inhibition (PI) has been reported to interfere with antibody‐driven autoimmune diseases. The impact of PI on the allergic immune response and on skin diseases like atopic dermatitis (AD) has not been thoroughly explored, however. Here, we examined whether the PI bortezomib interferes with the allergic immune response and the severity of AD by using an established mouse model of allergen‐driven dermatitis, to which bortezomib was applied after the establishment of systemic sensitization to ovalbumin. The treatment indeed resulted in a remarkable decrease in total and allergen‐specific plasma cells/antibody‐secreting cells, as evidenced by flow cytometry and ELISpot, respectively. This was accompanied by rapid reductions in serum antibody titres, including a prominent reduction of the IgE isotype. CD4+ and CD8+ cells were greatly diminished in lesional skin on immunohistological staining. The impressive effects at the level of immune modulation did not result in any improvement in the eczema, however. Following up on this unexpected result, we found that the skin itself was susceptible to bortezomib, by which it was instructed to lower the expression of critical skin barrier genes, especially transglutaminase‐1 and filaggrin. Together, bortezomib eliminates plasma cells and decreases immunoglobulin responses, including allergenic IgE. Although anti‐inflammatory effects are detectable in the skin, counter‐regulatory effects from PI on resident skin cells likely undermine improvement in the eczema. These results caution against the therapeutic use of bortezomib for inflammatory skin disorders, which are characterized by inherently impaired barrier function, especially AD. 相似文献
7.
8.
Jonathan I. Silverberg Emma Guttman-Yassky Melinda Gooderham Margitta Worm Stephanie Rippon Sean O’Quinn René van der Merwe Nana Kragh Azra Kurbasic Andreas Wollenberg 《Annals of allergy, asthma & immunology》2021,126(5):576-583.e4
BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes.MethodsThis was a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study in adults with moderate-to-severe AD. The patients received subcutaneous tralokinumab or placebo (1:1:1:1) every 2 weeks for 12 weeks and class 3 topical corticosteroid cream or ointment at least once daily from the run-in to end of follow-up. Patient-reported outcome end points were change from baseline to week 12 in the Dermatology Life Quality Index (dermatology life quality index (DLQI); prespecified secondary objective), the Short Form 36 Health Survey (SF-36) version 2, and sleep interference numeric rating scale score (prespecified exploratory objectives).ResultsA total of 204 patients were randomized to placebo (n = 51) or tralokinumab (45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52). Tralokinumab 300 mg every 2 weeks improved total Dermatology Life Quality Index vs placebo at week 12 (placebo-adjusted mean change, ?3.51 [95% confidence interval, ?6.00 to ?1.02]). At week 12, both the mental component summary (4.23 [0.98-7.47]) and the physical component summary (4.26 [1.83-6.69]) and all 8 domains of the Short Form 36 Health Survey were improved in patients treated with tralokinumab 300 mg vs placebo. Sleep interference was improved at week 12 with all tralokinumab doses vs placebo.ConclusionTralokinumab improved health-related QoL in patients with moderate-to-severe atopic dermatitis, providing further evidence of the value of targeting interleukin-13 in such patients.Trial RegistrationClinicalTrials.gov identifier: NCT02347176; https://clinicaltrials.gov/ct2/show/NCT02347176. 相似文献
9.